T. Rowe Price Associates
ORKA

T. Rowe Price Associates’s Oruka Therapeutics ORKA Stock Holding History

T. Rowe Price Associates’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.7M Buy
727,449
+78,103
+12% +$2.71M ﹤0.01% 878
2025
Q4 		$19.7M Buy
649,346
+22,540
+4% +$628K ﹤0.01% 1057
2025
Q3 		$12.1M Buy
626,806
+215,925
+53% +$3.2M ﹤0.01% 1180
2025
Q2 		$4.61M Sell
410,881
-721
-0.2% -$7.51K ﹤0.01% 1296
2025
Q1 		$4.22M Sell
411,602
-915,291
-69% -$11.4M ﹤0.01% 1298
2024
Q4 		$25.7M Buy
1,326,893
+1,047,245
+374% +$25.5M ﹤0.01% 929
2024
Q3 		$6.86M Buy
+279,648
New +$9.73M ﹤0.01% 1215

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

T. Rowe Price Associates's ORKA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Oruka Therapeutics (ORKA) stake by 12% in Q1 2026, buying an estimated $2.71M and bringing the position to 727,449 shares worth $35.7M. The position accounts for ﹤0.01% of the portfolio, ranked #878.

T. Rowe Price Associates first reported a position in ORKA in Q3 2024 and has held it in 7 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • T. Rowe Price Associates held 727,449 shares of Oruka Therapeutics worth $35.7M as of Q1 2026.
  • T. Rowe Price Associates bought 78,103 Oruka Therapeutics shares in Q1 2026, an estimated $2.71M.
  • Oruka Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #878 holding.
  • T. Rowe Price Associates first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.